November 07, 2023
1 min watch
Save
VIDEO: ‘New potential standard-of-care option’ for EGFR exon 20 insertion-mutated NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MADRID — There were “many exciting updates in EGFR” in the advanced-stage lung cancer setting at ESMO Congress, according to Julia Rotow, MD.
Rotow, clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discussed positive data from the PAPILLON trial in a video interview. The study showed improvement in clinical outcomes with amivantamab (Rybrevant, Janssen) plus chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
“I think this is a new potential standard-of-care option for this particular patient population in the first-line setting,” she said.
Reference:
- Girard N, et al. Abstract LBA5. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Rotow reports numerous ties to industry.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.